kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human Flt3-Ligand Protein,HEK293 Expressed, 50µg  

Recombinant Human Flt3-Ligand Protein,HEK293 Expressed, 50µg

ActiveMax® Recombinant human Flt-3 Ligand Protein / FLT3LG (rhFLT3LG) Thr27-Pro185 was produced in human HEK293 cells, ActiveMaxCytokine, Tag Free

 Synonyms: FLT3LG, FL, FLT3L, FLT3-LG, FLT-3L, Fms-related tyrosine kinase 3 ligand, FLT3 ligand

More details


Availability: within 7 days

408,00 €

Background: FMS-like tyrosine kinase 3 ligand (Flt-3 Ligand), also known as FL, Flt3L and FLT3LG, is an α-helical cytokine that promotes the differentiation of multiple hematopoietic cell lineages (1). FLT3LG is expressed as a noncovalentlylinked dimer by T cells and bone marrow and thymic fibroblasts (1, 2). Each 36 kDa chain carries approximately 12 kDa of N- and O- linked carbohydrates (2). FLT3LG is structurally homologous to stem cell factor (SCF) and colony stimulating facor 1 (CSF-1). FLT3LG acts as a growth factor that increases the number of immune cells by activating the hematopoietic progenitors. It also induces the mobilization of the hematopoietic progenitors and stem cells in vivo which may help the system to kill cancer cells. FLT3LG induces the expansion of monocytes and immature dendritic cells as well as early B cell lineage differentiation (2-3). FLT3LG cooperates with IL2, IL6, IL7, and IL15 to induce NK cell development and with IL3, IL7 and IL11 to induce terminal B cell maturation (1, 4). Animal studies also show FLT3LG to reduce the severity of experimentally induced allergic inflammation. FLT3LG is crucial for steady-state pDC and cDC development.[5] A lack of FLT3L results in low levels of DCs.

Recombinant ActiveMax® Human Flt-3 Ligand, Tag Free (FLL-H5218) is expressed from human 293 cells (HEK293). It contains AA Thr 27 - Pro 185 (Accession # AAI26294).
Predicted N-terminus: Thr 27

Molecular Characterization
This protein carries no "tag".
The protein has a calculated MW of 18.0 kDa. The protein migrates as 21-27 kDa under reducing (R) condition (SDS-PAGE).

Less than 1.0 EU per 1 μg of the rhFLT3LG by the LAL method.

>95% as determined by SDS-PAGE. All lots are greater than 95% pure.

Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Please refer to product data sheet.

Clinical and Translational Updates

(1) "Dendritic cells play no significant role in the laser-induced choroidal neovascularization model"
Droho, Perlman, Lavine
Sci Rep (2021) 11 (1), 17254
(2) "Multimodal Intralesional Therapy for Reshaping the Myeloid Compartment of Tumors Resistant to Anti-PD-L1 Therapy via IRF8 Expression"
Patel, Oba, Kajihara et al
J Immunol (2021) 207 (5), 1298-1309
(3) "Cellular Basis for the Enhanced Efficacy of the Fms-Like Tyrosine Kinase 3 Ligand (FL) Adjuvanted VCG-Based Chlamydia abortus Vaccine"
Richardson, Medhavi, Tanner et al
Front Immunol (2021) 12, 698737
Showing 1-3 of 1388 papers.